Partner 5 – IMM (Vice-Coordinator)
Immatics is a leading clinical-stage biopharmaceutical company working on the rational discovery and development of peptide-based cancer immunotherapeutics. Immatics’ lead product for treatment of renal cell carcinoma, IMA901, is currently developed in a pivotal phase 3 study after completing a successful phase 2 trial (1). The company’s pipeline also includes the vaccine IMA910, which has recently completed a phase 1/2 study in colorectal cancer, and IMA950, currently tested in multiple phase 1 studies for glioblastoma. Immatics is a spin-off company from the University of Tuebingen (partner TUE) and currently employs 80 employees at offices in Tuebingen and Munich, Germany.